ARTICLE. Keywords: TSC1 and TSC2; tuberous sclerosis complex; genotype phenotype correlation

Size: px
Start display at page:

Download "ARTICLE. Keywords: TSC1 and TSC2; tuberous sclerosis complex; genotype phenotype correlation"

Transcription

1 (2005) 13, & 2005 Nature Publishing Group All rights reserved /05 $ ARTICLE Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex Ozgur Sancak 1, Mark Nellist 1, Miriam Goedbloed 1, Peter Elfferich 1, Cokkie Wouters 1, Anneke Maat-Kievit 1, Bernard Zonnenberg 3, Senno Verhoef 2, Dicky Halley 1 and Ans van den Ouweland*,1 1 Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands; 2 Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands; 3 TSC Clinic, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by the development of hamartomas in multiple organs and tissues. TSC is caused by mutations in either the TSC1 or TSC2 gene. We searched for mutations in both genes in a cohort of 490 patients diagnosed with or suspected of having TSC using a combination of denaturing gradient gel electrophoresis, single-strand conformational polymorphism, direct sequencing, fluorescent in situ hybridisation and Southern blotting. We identified pathogenic mutations in 362 patients, a mutation detection rate of 74%. Of these 362 patients, 276 had a definite clinical diagnosis of TSC and in these patients 235 mutations were identified, a mutation detection rate of 85%. The ratio of TSC2:TSC1 mutations was 3.4:1. In our cohort, both TSC1 mutations and mutations in familial TSC2 cases were associated with phenotypes less severe than de novo TSC2 mutations. Interestingly, consistent with other studies, the phenotypes of the patients in which no mutation was identified were, overall, less severe than those of patients with either a known TSC1 or TSC2 mutation. (2005) 13, doi: /sj.ejhg Published online 30 March 2005 Keywords: TSC1 and TSC2; tuberous sclerosis complex; genotype phenotype correlation Introduction Tuberous sclerosis complex (TSC, MIM #191100), affecting between 1/6000 and 1/ individuals, is an autosomal dominant disorder characterised by seizures, mental retardation and the development of hamartomas in multiple organs and tissues. 1 In approximately two-thirds of cases *Correspondence: Dr A van den Ouweland, Department of Clinical Genetics, Erasmus Medical Center, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. Tel: þ ; Fax: þ ; a.vandenouweland@erasmusmc.nl Received 27 October 2004; revised 4 February 2005; accepted 8 February 2005 neither parent has signs of TSC and the disease is caused by a de novo mutation, indicating a high rate of spontaneous mutation in the causative genes, TSC1 and TSC2. The TSC1 gene consists of a 3.4-kb open reading frame encoded by 21 exons, whereas the 5.4 kb open reading frame of the TSC2 gene is encoded by 41 exons. Loss of heterozygosity across the TSC1 and TSC2 loci in TSCassociated lesions indicates that TSC1 and TSC2 are tumor suppressor genes. 2 The TSC1 and TSC2 gene products, hamartin and tuberin, form a complex 3 that activates the GTPase activity of rheb, preventing the rheb-gtp-dependent stimulation of cell growth through mtor. 4

2 732 A broad spectrum of mutations has been identified in both genes Interestingly, large rearrangements, missense mutations and in-frame deletions are very rare in the TSC1 gene. The majority of TSC patients have a mutation in the TSC2 gene. In de novo cases, mutations in the TSC2 gene are found two to ten times more often than TSC1 mutations In contrast, in multi-generation families segregating TSC, approximately half show linkage to TSC1 and half to TSC2. 13 It has been suggested that this may be because TSC patients with a TSC1 mutation are less likely to be severely affected and therefore more likely to have offspring. 12 Although initially the broad phenotypic and genotypic spectra of TSC made it difficult to establish an association, 7,11 studies of larger cohorts indicated that patients with a TSC1 mutation were less likely to be mentally retarded, 9 while patients with a TSC2 mutation had a higher number and/or severity of clinical features. 10 We have performed a comprehensive screen for mutations at the TSC loci and compared the phenotypes within a large unrelated TSC patient cohort including the previously described group of patients. 7 The majority of TSC patients in our cohort have a mutation in the TSC2 gene, and, overall, TSC2 mutations are associated with a more severe TSC phenotype. Our analysis confirms and extends the findings of previous studies. Materials and methods Patients Samples from patients with a (putative) diagnosis of TSC were obtained via several specialists in the Netherlands and abroad. A standardised clinical evaluation form was sent to all the referring clinicians. In familial cases, only index patients were used for phenotypic comparisons. Mutation analysis DNA was extracted from peripheral blood cells using standard techniques. Mutation analysis was performed using a combination of single-strand conformational polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), direct sequencing, Southern blotting and fluorescence in situ hybridisation (FISH). SSCP, Southern and FISH analyses were performed as described previously. 14,15 For DGGE, primers were designed using the Ingeny DGGE Primer Design program (primer sequences available upon request), and pooled PCR products were run on urea/formamide denaturing gradient polyacrylamide gels at 601C for 17 h (Ingeny phoru DGGE system). SSCP was performed on 50% of the patients and DGGE on 75% of the cohort. One exon in TSC1 and five exons in TSC2 were not suitable for DGGE and were sequenced. If no mutation was identified, Southern blotting and FISH analysis were undertaken. Direct sequencing of M13-tagged PCR products was carried out on an ABI3100 capillary sequencer using Big Dye Terminator v 3 chemistry (Applied Biosystems). A nucleotide change was classified as a polymorphism when this change was present in the patient together with a pathogenic mutation, when it was present in the DNA of the unaffected parent of the patient or when it had been classified as a polymorphism in the literature. A complete overview of our mutation analysis strategy is available upon request. Total RNA was isolated from cultured patient fibroblasts. RT-PCR was performed according to standard procedures. Functional analysis of the effect of TSC2 missense changes on the tuberin hamartin complex was performed as described previously. 16,17 Statistical analysis Statistical comparisons were performed using the SPSS version 11.0 package for PC. Pearson w 2 or Fisher s exact test was used for comparisons of categorical data and Mann Whitney test was used for the comparison of median age at referral. Results Patient characteristics Mutation analysis of the TSC1 and TSC2 genes was performed on 490 patients with a (putative) diagnosis of TSC (Table 1). In 276 cases, sufficient clinical information was obtained to make a definite diagnosis of TSC according to the criteria defined by Roach et al. 18 In 15 cases there was insufficient data for a definite diagnosis and in 199 cases we did not receive any clinical data. The 291 patients with clinical information were between 0 and 60 years old at the time of referral, with a median age of We examined the correlation between different clinical features in the 276 definitive TSC patients. The majority of the patients were mentally retarded (166/276; 60%), and 163 of these patients (98%) had seizures. In contrast, only 37 of the 63 patients without mental retardation had seizures (59%). This difference was significant (Po0.001). Seizures were present in 86% of the patients with (sub)- cortical tubers and in 56% of the patients free of tubers (P ¼ 0.004). The presence of (sub)cortical tubers also correlated with the presence of mental retardation. Of the patients with (sub)cortical tubers 82% had mental retardation, while only 33% of the patients without tubers were mentally retarded (P ¼ 0.002). Subependymal nodules were noted in 88% of the patients with (sub)cortical tubers and in 63% of the patients without tubers (P ¼ 0.013). In addition, there was a significant correlation between the incidence of renal angiomyolipomas and mental retardation in patients above the age of 6 years at referral. The patients with renal angiomyolipoma (82%) had more frequently mental retardation compared to the patients without renal angiomyolipoma (64%)(P ¼ 0.041). Comparison of the clinical features between male and female subjects showed no significant difference in the

3 733 Table 1 Overview of the TSC patient cohort Total Mutation identified Unclassified variant No mutation identified TSC1 mutation TSC2 mutation De novo Familial Patients with clinical information Def. TSC Insuf. information Total No clinical information Total Groups with a definite diagnosis of TSC (Def. TSC), insufficient clinical information for a definite diagnosis (Insuf. information) and without any clinical information (No clinical information) are shown. For each group, patients with mutations in the TSC1 and TSC2 genes in addition to patients with nucleotide changes that could not yet be classified as pathogenic (unclassified variant) are depicted. The number of patients with de novo mutations and of patients of familial cases (based on molecular analysis) are also shown. Table 2 Comparison of the clinical features of TSC associated with gender Male Female P/N % P/N % P-values Mental retardation 89/ / * Seizures 110/ / Cortical tubers 56/ / SEN 84/ / SEGA 9/ / Renal AML 31/ / Renal cysts 22/ / Shagreen patch 30/ / Hypomelanotic macules 94/ / Forehead plaque 23/ / Facial angiofibromas 82/ / * Ungual fibroma 28/ / Retinal phakoma 26/ / * Retinal depigmentation 11/ / * Gingival fibroma 10/ / * Dental pits 20/ / Cardiac rhabdomyoma 23/ / LAM 0/19 0 4/ For each group, the first column shows the number of patients with the feature (P) and the total number of patients examined (N) and the second column shows the frequency of each clinical feature (%). *Indicates statistically significant values. Median age was 14.0 years for males and 13.0 years for females (P ¼ 0.467) (SEN, subependymal nodules; SEGA, subependymal giant cell astrocytoma; AML, angiomyolipoma; LAM, lymphangioleiomyomatosis). median age of the two groups (P ¼ 0.467) (Table 2). However, 75% of the clinical features analysed were more frequent in males. Mental retardation (P ¼ 0.012), facial angiofibromas (P ¼ 0.050), retinal phakomas (P ¼ 0.025), retinal depigmentations (P ¼ 0.005) and gingival fibromas (P ¼ 0.019) were noted significantly more frequently in males. Lymphangioleiomyomatosis (LAM) was only detected in females (four cases). However, due to the low numbers of patients examined for LAM (12 males and 21 females), this difference was not significant (P ¼ 0.146). Mutation analysis We identified pathogenic mutations in 362 patients (74% of the total cohort), 82 mutations in the TSC1 gene and 280 in the TSC2 gene (23% 77%). The different types of TSC1 and TSC2 mutations are shown in Figure 1. In addition, we identified 20 different polymorphisms in the TSC1 gene and 56 in the TSC2 gene. In 29 cases (6% of the total), we detected nucleotide changes in the TSC2 gene, but were unable to establish whether they were pathogenic. A complete

4 734 Figure 1 Types and frequencies of the mutations identified at the TSC1 and TSC2 loci. (& frameshift mutations, in-frame deletions, nonsense mutations, splice site mutations, missense mutations, large rearrangements). overview of all the changes identified at both loci is available on request. When possible, the parents of the patient were tested for the presence of a (putative) pathogenic mutation (Table 1). In 137 cases (22 TSC1 and 115 TSC2), the change identified in the patient was not present in the DNA of either parent. We defined these cases as de novo TSC. In 63 cases (20 TSC1 and 43 TSC2) the same pathogenic change was identified in the affected parent of the patient. In 10 cases, we could not rule out the possibility that a change identified in both the patient and another affected parent was nonpathogenic. In 181 cases the parents were not available for testing. Four nucleotide changes in the TSC2 gene showed a possible effect on RNA splicing using three different splice-site prediction programs ( tools/splice.html; and RT- PCR analysis showed an incorrectly spliced TSC2 mrna in three cases, confirming that the changes were pathogenic. In one case (IVS5 þ 4A4G) we were unable to detect any abnormally spliced variant. However, further investigation revealed that the expression of the mutant allele was severely reduced. In several cases the effects of TSC2 missense mutations on tuberin function were investigated. Missense changes that inactivated tuberin in vitro were classified as pathogenic. In cases where we could not demonstrate that missense and intronic changes were de novo or had an effect on splicing or the function of the tuberin hamartin complex, we designated the changes as unclassified variants. Previously we described two cases of mosaicism at the TSC1 locus and four cases at the TSC2 locus in the parents of TSC patients. 14 We have identified two additional cases of mosaicism in the TSC2 gene, one large de novo deletion in a patient (80% of the cells) and one nonsense mutation (3112C4T (R1032X)) in the father of a familial case of TSC. In 94 patients where both SSCP and DGGE were performed and a mutation was identified, 87 mutations (93%) were identified by DGGE, and 79 mutations (84%) were identified by SSCP. In 71 (76%) cases the mutation was identified by both techniques. In the TSC2 gene, seven changes were detected by SSCP but not by DGGE, while seven changes in the TSC1 gene and eight changes in the TSC2 gene were detected by DGGE but not by SSCP. Large rearrangements of the TSC2 gene were identified by FISH and/or Southern blotting in 20 patients, accounting for 7% of the TSC2 mutations. Of these, three were complete gene deletions, 12 were on one end of the gene, four were intragenic and one was an intragenic duplication. In 50% of cases the rearrangement was detected by both techniques. Recurrent mutations were identified at both loci. The most common mutation was the 1850G4A (R611Q) missense mutation in exon 16 of the TSC2 gene which was detected in 10 unrelated patients and, together with the adjacent 1849C4T (R611W) mutation that was detected in an additional four cases, accounted for 3.8% of the mutations identified. The most frequently occurring TSC1 mutation, 1719C4T (R500X), was detected in six cases (1.7% of the total mutations). The distributions of small mutations within the TSC1 and TSC2 genes are shown in Figure 2. The most mutations in the TSC1 gene were identified in exon 15 (19/362; 5.2% of total mutations) and in the TSC2 gene in exon 32 (32/362; 8.8% of total mutations). No mutations were identified in exons 3, 19, 22 and 23 of the TSC1 gene or in exon 30B of the TSC2 gene. We calculated the mean number of mutations (including splice site changes) per nucleotide for each exon of both genes. The overall mutation frequency was higher at the TSC2 locus (0.045 mutations per nucleotide) than at the TSC1 locus (0.020 mutations per nucleotide). However, as shown in Figure 2, there was considerable variation in the frequency of

5 735 Figure 2 The distribution of small mutations along the TSC1 and the TSC2 genes (K missense mutations and in-frame deletions, nonsense and frameshift mutations, splice site mutations). Alternatively spliced exons in the TSC2 gene are depicted in black. The mutation rate per nucleotide in each exon is graphed above each exon. The figures were calculated by dividing number of small mutations within the exon and the splicing mutations within five nucleotides in the 3 0 and 5 0 regions of the exon by the number of nucleotides of the exon plus 10 nucleotides for the surrounding intronic area. Note, exons are not drawn to scale. mutations per exon. Exons 16 and 39 of the TSC2 gene had the highest frequency of mutations. Exons of the TSC2 gene encode the GTPase activating-protein (GAP) domain which is essential for tuberin function. We identified 64 small nucleotide mutations within these five exons, accounting for almost 18% of all the mutations identified. Interestingly, 46% of all the missense mutations and 93% of all the in-frame deletion mutations identified in the TSC2 gene were in this region. Phenotypic comparisons We obtained clinical information on 291 patients, of which 276 (95%) fulfilled the definite TSC diagnostic criteria. In these 276 patients we identified 235 mutations; 53 in the TSC1 gene and 182 in the TSC2 gene, a mutation detection rate of 85%. In 15 individuals where there was insufficient clinical evidence for a definite diagnosis of TSC, we identified four mutations. In two cases (mutations: TSC1 903C4T (R228X) and TSC2 4324delC), the patients were mentally retarded, had seizures, radiological brain abnormalities and hypomelanotic macules; in one case (mutation TSC2 1135C4T (Q373X)) dental pits and facial angiofibroma were noted in combination with epilepsy and mental retardation; and in one case (mutation TSC2 4324C4T (R1436X)), subependymal nodules were the only clinical feature noted. We compared patients with a TSC1 mutation to those with a TSC2 mutation (Tables 3a and 3b). The median age of the patients with a TSC1 mutation was not significantly

6 Table 3a Comparison of the clinical features in TSC patients with and without mutations TSC1 TSC2 Total Familial De novo Total Familial De novo Mutations Total Familial De novo No Mutation Identified P/N % P/N % P/N % P/N % P/N % P/N % P/N % P/N % P/N % P/N % Mental retardation 19/ / / / / / / / / /22 36 Seizures 42/ / / / / / / / / /25 68 Cortical tubers 20/ / / / / / / / / /18 78 SEN 34/ / / / / / / / / /22 82 SEGA 5/ /3 67 1/ / /6 33 7/ / /9 44 8/ /14 7 Renal AML 2/27 7 0/5 0 0/ / / / / / / /16 56 Renal cysts 3/ /5 20 0/ / / / / / / /16 31 Shagreen patch 22/ /9 78 5/ / / / / / / /16 19 Hypomelanotic macules 41/ / / / / / / / / /23 74 Forehead plaque 6/ /8 25 2/ / / / / / / /15 13 Facial angiofibromas 27/ / / / / / / / / /22 64 Ungual fibroma 14/ /8 25 1/ / / / / / / /15 27 Retinal phakoma 3/ /9 0 2/ / / / / / / /16 13 Retinal depigmentation 0/8 0 0/1 0 0/2 0 11/ /4 25 6/ / /5 20 6/ /10 10 Gingival fibroma 5/ / / / /1 0 6/ / /3 67 7/ /5 40 Dental pits 10/ /4 50 2/ / / / / / / /4 25 Cardiac rhabdomyoma 10/ /3 33 6/ / / / / / / /15 33 Familial represents the index patients of familial cases. For each group, the first column shows the number of patients with the feature (P) and the total number of patients examined (N) and the second column shows the frequency of each clinical feature (%). The median age was 14.0 for TSC1 familial, 4.0 for TSC1 de novo, 15.0 for TSC1 total, 11.0 for TSC2 familial, 10.0 for TSC2 de novo, 12.0 for TSC2 total, 13.0 for mutations total, 9.5 for de novo, 11.5 for familial and 12.0 for no mutation identified groups (SEN, subependymal nodules; SEGA, subependymal giant cell astrocytoma; AML, angiomyolipoma). 736

7 Table 3b Significance (P) values of the comparisons made between the different groups depicted in table 3a TSC1 TSC2 Familial de novo TSC2 familial TSC2 de novo TSC1 de novo TSC2 de novo TSC1 familial TSC2 familial TSC1 familial TSC1 de novo No mutation mutations total No mutation TSC1 total Mental retardation o0.001* o0.001* Seizures * * 0.016* Cortical tubers SEN * o0.001* SEGA Renal AML o0.001* * ** * Renal cysts 0.050* * Shagreen patch 0.031* * * 0.001* Hypomelanotic macules * ** * 0.037* Forehead plaque * Facial angiofibromas Ungual fibroma Retinal phakoma 0.003* 0.030* Retinal depigmentation ** Gingival fibroma Dental pits Cardiac rhabdomyoma Median age * *Indicates statistically significant values. Familial represents the index patients of familial cases (SEN, subependymal nodules; SEGA, subependymal giant cell astrocytoma; AML, angiomyolipoma). **Indicates where statistical analysis could not be performed, since the patients in both groups were either all positive or all negative for the analysed feature. 737

8 738 different from the median age of those with a TSC2 mutation (P ¼ 0.321). However, individuals with a TSC1 mutation were less often mentally retarded (Po0.001), and renal angiomyolipomas (Po0.001), renal cysts (P ¼ 0.050), retinal phakomas (P ¼ 0.003) and retinal depigmentations (P ¼ 0.073) were all less frequent in the TSC1 mutation group. In contrast, shagreen patches occurred significantly more frequently in patients with a TSC1 mutation (P ¼ 0.031). Interestingly, although the incidence of mental retardation was lower in the group of patients with a TSC1 mutation, the incidences of seizures (P ¼ 0.595) and (sub)cortical tubers (P ¼ 0.299) were not significantly different between the two groups. We compared the phenotypes of individuals with a TSC2 (i) nonsense or frameshift mutation; (ii) missense mutation; (iii) large abnormality; and (iv) mutation in exons (encoding the GAP domain). Both renal angiomyolipomas and renal cysts were more frequent in the group with nonsense and frameshift mutations (64% and 37%, respectively) than in the group with missense mutations (38% and 24%, P ¼ and 0.367), or mutations in the GAP domain (39% and 10%, P ¼ and 0.018). Shagreen patches, forehead plaques, facial angiofibromas and ungual fibromas also occurred more often in the group of patients with a nonsense or frameshift mutation. The incidence of renal cysts was highest in the group of patients with large abnormalities of the TSC2 gene (out of 10 patients with clinical information, three patients with a whole gene deletion and one patient with an intragenic duplication had renal cysts). Mental retardation, seizures and subependymal nodules occurred most frequently in the group of patients with a mutation in the GAP domain. Next, we compared the clinical features in the 50 familial cases to the clinical features in the 91 individuals with a de novo mutation (Tables 3a and 3b). The median age was higher in the familial cases (P ¼ 0.226) and many clinical manifestations were less frequent. For subependymal nodules (P ¼ 0.001) and retinal phakomas (P ¼ 0.030) the differences were significant. In contrast, hypomelanotic macules were significantly more frequent in the familial cases (P ¼ 0.034). In our cohort, TSC2 mutations were associated with a more severe phenotypic spectrum than TSC1 mutations (see above and Tables 3a and 3b). In addition, the proportion of de novo cases with a TSC2 mutation (115/ 137; 84%) was higher than the proportion of familial cases with a TSC2 mutation (43/63; 68%) (P ¼ 0.125), consistent with the more severe phenotypic spectrum observed in the de novo group. We compared the clinical features of familial and de novo cases with either a TSC1 or a TSC2 mutation. As shown in Tables 3a and 3b, 14 out of 17 clinical features were more frequent in the group of patients with a de novo TSC2 mutation, than in the group with a familial TSC2 mutation. Seizures and subependymal nodules occurred significantly more frequently in the de novo group (P ¼ and Po0.001, respectively). The median age at referral was not significantly different between patients with a de novo TSC2 mutation and familial cases (P ¼ 0.921). In contrast, patients with a familial TSC1 mutation were referred for DNA testing at a significantly older age than patients with a de novo TSC1 mutation (P ¼ 0.027). Subependymal nodules, forehead plaques, retinal phakoma and cardiac rhabdomyoma were more frequent in the group with a de novo TSC1 mutation compared to the group with a familial TSC1 mutation. Next, we compared the clinical features in the group of patients with a de novo TSC1 mutation to the group with a de novo TSC2 mutation. The majority of clinical features (14/17) were seen at a lower frequency in the group with a de novo TSC1 mutation. Notably, mental retardation (P ¼ 0.055), renal angiomyolipomas (P ¼ 0.011) and renal cysts (P ¼ 0.048) were less frequent in the group with a de novo TSC1 mutation. The median age at referral was not significantly different (P ¼ 0.364). The phenotypic differences between the familial cases with TSC1 and TSC2 mutations were less pronounced. The only significant difference was the higher frequency of shagreen patches in the group with TSC1 mutations (P ¼ 0.035). The median age at referral was not significantly different between these two groups (P ¼ 0.119). The clinical manifestations in 27 individuals with clinically definite TSC, without an identified pathogenic mutation, were compared to patients with definite TSC and an identified pathogenic mutation (Tables 3a and 3b). Although the median age at referral in the two groups was not significantly different (P ¼ 0.795), many of the clinical features including mental retardation (Po0.001), seizures (P ¼ 0.001), shagreen patches (P ¼ 0.006), hypomelanotic macules (P ¼ 0.006) and forehead plaques (P ¼ 0.033) occurred at a significantly lower frequency in the group without an identified mutation. Other symptoms were also observed less frequently in this group, although the differences were not statistically significant (p40.05). Since the group of patients with a TSC1 mutation was also associated with a less severe phenotype, we compared the clinical features in the group without an identified mutation to the group with a TSC1 mutation. Most clinical features (13/17) were less frequent in the no mutation group. In particular, seizures (P ¼ 0.016), shagreen patches (P ¼ 0.001) and hypomelanotic macules (P ¼ 0.037) occurred less frequently. In contrast, renal angiomyolipomas (P ¼ 0.001) and renal cysts (P ¼ 0.100) were more common in the no mutation group. Discussion Using a combination of DGGE, SSCP, FISH and Southern analysis, a total of 362 mutations were identified in 490

9 739 patients (74%); of these, 235 mutations were present in 276 patients fulfilling the TSC definitive diagnostic criteria (85%), comparable to earlier studies. 9,10,19 The detection rate dropped to 62% in the group of patients without any clinical information and to 27% in patients where the clinical evidence was not sufficient for a definitive diagnosis. This suggests that our cohort contains individuals that have been misdiagnosed with TSC and that, in many patients, good clinical work-up will be sufficient to make a definite diagnosis of TSC. However, in some cases, molecular genetic screening of patients with an incomplete clinical evaluation can assist in establishing the diagnosis. We identified significant correlations between the presence of mental retardation and seizures and the presence of (sub)cortical tubers and mental retardation similar to previous studies. 10 In addition, we identified significant correlations between the presence of seizures and (sub)- cortical tubers, and between the presence of (sub)cortical tubers and subependymal nodules. Consistent with earlier work, we found a correlation between the incidence of renal angiomyolipomas and mental retardation in patients above 6 years of age. 10,20 In our cohort, males with TSC were more likely to be mentally retarded and to have renal cysts, retinal lesions, facial angiofibromas, and gingival and ungual fibromas. Sex-linked differences in TSC-associated features have been described previously in humans and in animal models of the disease. For example, males with TSC have a greater risk of learning disorders and autism than females with the disease. 21 In addition, sex hormones have been shown to affect the behaviour of cells derived from TSC-associated lesions 22 and in a mouse model of TSC, liver hemangiomas were more common and more extensive in female than in male mice. 23 It will be interesting to investigate in more detail how sex hormones regulate the functions of tuberin and hamartin, and to determine how hormonal changes influence the TSC phenotype. Previous studies of large numbers of TSC patients have used denaturing high-performance liquid chromatography (DHPLC) for the detection of small nucleotide changes in the TSC1 and TSC2 genes. 10,19 Although we used a different approach, we detected a similar spectrum of small TSC1 and TSC2 mutations. In 94 cases where both SSCP and DGGE were performed and a mutation was identified, DGGE had a slightly higher mutation detection rate (93%) than SSCP (84%). For various technical reasons, a small number of mutations at the TSC1 and TSC2 loci are likely to be missed by either SSCP or DGGE. Due to its higher capacity and sensitivity, DGGE is now the method of choice in our laboratory. Exons not amenable to DGGE analysis, are directly sequenced. To detect larger rearrangements at the TSC2 locus, we performed FISH and Southern blotting. Neither technique alone detected all of the rearrangements in our cohort and therefore we are currently developing a multiplex ligation-dependent probe amplification assay (MLPA). We found a similar predominance of TSC2 mutations in both de novo and familial cases as previous studies. 9 11,24 We also confirmed the lower frequency of de novo TSC1 mutations compared to de novo TSC2 mutations, which has been attributed to the smaller size and less complex structure of the TSC1 genomic locus, and the rarity of large DNA rearrangements, missense and splice site mutations at this locus. 24 It has also been suggested that TSC1 mutations are associated with a less severe TSC phenotype. 9,10 In our cohort, individuals with a TSC1 mutation were less likely to be mentally retarded than patients with a TSC2 mutation, even though the incidence of tubers and seizures in the group of patients with a TSC1 mutation was not significantly lower. Previous studies have suggested that there is a correlation between tuber number and mental retardation in TSC patients and that, on average, fewer tubers and subependymal nodules are found in patients with a TSC1 mutation. 10 We were unable to obtain data on the number of tubers to determine whether this could explain the lower incidence of mental retardation in the patients with a TSC1 mutation in our cohort. Renal and retinal abnormalities occurred less frequently in the group of patients with a TSC1 mutation, consistent with other studies. 9,10 Although the incidence of dermatological abnormalities was not significantly reduced in this group, shagreen patches were present significantly more often. The lower incidence of renal abnormalities in this group, in contrast to the approximately equal incidence of brain and skin lesions, is consistent with the proposal that at least some of the phenotypic differences between these two groups is due to a differential role of tuberin and hamartin in renal cell growth control. 25 We identified a lower proportion of TSC2 mutations in familial cases of TSC than in de novo cases (68 84%). We compared the clinical features of both familial and de novo cases of TSC caused by mutations to either gene. Similar to the comparison of the cohort as a whole (see above), de novo TSC1 mutations were associated with a lower frequency of clinical features than de novo TSC2 mutations. In familial cases, however, there was less difference between the clinical features of the groups of patients with a TSC1 or TSC2 mutation. This suggested that familial cases with a TSC2 mutation are associated with a milder TSC phenotype than de novo TSC2 cases, which was supported by a comparison of the frequencies of their clinical features. We did not detect any significant phenotypic differences between familial and de novo cases with a TSC1 mutation. The mutation frequency, as calculated per exonic nucleotide, at the TSC2 locus was higher compared to that at the TSC1 locus and, not surprisingly, the exons with the highest frequencies of mutation (TSC2 exons 16 and 39)

10 740 both contained recurrent mutations. The high proportion of nontruncating mutations in exons of the TSC2 gene supports previous findings that the GAP domain of the TSC2 gene is a target for missense mutations. 26 The frequencies of neurological symptoms and some brain lesions were slightly higher and the incidence of renal abnormalities was lower in patients with mutations in exons than in other groups. These differences were not significant. Overall, we could not confirm that mutations to the tuberin GAP domain are associated with a more severe phenotype. 26 The high incidence of renal cysts in the group with large abnormalities is consistent with the disruption of the adjacent PKD1 gene in several of these cases. 1 In 27 patients with definite TSC, we did not identify a mutation in either the TSC1 or TSC2 gene. Most clinical features, with the exception of renal abnormalities and gingival fibromas, occurred less frequently in this group of patients compared to the group with a mutation. It is possible that mutations in regulatory regions that impair gene transcription or translation account for the milder phenotypes of these cases. Somatic mosaicism may also explain why in some patients no mutations were detected. 10 Recently, Roberts et al 27 reported somatic mosaicism in 3% of patients diagnosed with definite TSC. We have identified eight cases of somatic mosaicism: only one patient and seven parents of a patient. Since we stopped using an allele specific method for family studies, it is possible that some mosaic parents have been missed. It is likely that there are more mosaic patients in our cohort with a degree of mosaicism below the detection limit of the current screening protocol. In summary, in our diagnostic setting of TSC mutation analysis an overall mutation detection rate of 74% was obtained; a pathogenic mutation was identified in 85% of definite TSC patients. Our study reveals that several clinical manifestations of TSC occur more frequently in males. In addition, TSC2 mutations are associated with a more severe phenotype than TSC1 mutations, and the group of patients with a de novo TSC2 mutation have a more severe phenotypic spectrum than the group of patients with a familial TSC2 mutation. The identification of a TSC1 or a TSC2 mutation will not only confirm the diagnosis of TSC but will also be important for both clinical management and possible therapeutic or preventive measures. Acknowledgements We thank all the patients who contributed DNA samples for analysis, and the referring clinicians. Gregory Asmawidjaja, Anita Jankie, Kim van Zijl, Rodney Blenham and Margje van Schaik are thanked for technical assistance. This work was supported by the Nationaal Epilepsie Fonds, Noortman BV, the Nederlandse Organisatie voor Wetenschappelijk Onderzoek and the Department of Clinical Genetics at the Erasmus MC. References 1 Gomez M, Sampson J, Whittemore V: The Tuberous Sclerosis Complex. Oxford, England, Oxford University Press, Henske EP, Scheithauer BW, Short MP et al: Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996; 59: Nellist M, van Slegtenhorst MA, Goedbloed M, van den Ouweland AM, Halley DJ, van der Sluijs P: Characterization of the cytosolic tuberin hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J Biol Chem 1999; 274: Garami A, Zwartkruis FJ, Nobukuni T et al: Insulin activation of Rheb, a mediator of mtor/s6k/4e-bp signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11: Identification and characterization of the tuberous sclerosis gene on chromosome 16: The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 1993; 75: van Slegtenhorst M, de Hoogt R, Hermans C et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: van Slegtenhorst M, Verhoef S, Tempelaars A et al: Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype phenotype correlation. J Med Genet 1999; 36: Au KS, Rodriguez JA, Finch JL et al: Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients. Am J Hum Genet 1998; 62: Jones AC, Shyamsundar MM, Thomas MW et al: Comprehensive mutation analysis of TSC1 and TSC2 and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64: Dabora SL, Jozwiak S, Franz DN et al: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: Niida Y, Lawrence-Smith N, Banwell A et al: Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat 1999; 14: Langkau N, Martin N, Brandt R et al: TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios. Eur J Pediatr 2002; 161: Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ: Molecular genetic advances in tuberous sclerosis. Hum Genet 2000; 107: Verhoef S, Bakker L, Tempelaars AM et al: High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 1999; 64: Eussen BH, Bartalini G, Bakker L et al: An unbalanced submicroscopic translocation t(8;16)(q24.3;p13.3)pat associated with tuberous sclerosis complex, adult polycystic kidney disease, and hypomelanosis of Ito. J Med Genet 2000; 37: Nellist M, Verhaaf B, Goedbloed MA, Reuser AJ, van den Ouweland AM, Halley DJ: TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin hamartin complex. Hum Mol Genet 2001; 10: Nellist M, Sancak O, Goedbloed MA et al: Distinct effects of single amino-acid changes to tuberin on the function of the tuberinhamartin complex. Eur J Hum Genet 2005; 13: Roach ES, DiMario FJ, Kandt RS, Northrup H: Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14: Jones AC, Sampson JR, Hoogendoorn B, Cohen D, Cheadle JP: Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet 2000; 106: O Callaghan FJ, Noakes M, Osborne JP: Renal angiomyolipomata and learning difficulty in tuberous sclerosis complex. J Med Genet 2000; 37:

11 Smalley SL, Tanguay PE, Smith M, Gutierrez G: Autism and tuberous sclerosis. J Autism Dev Disord 1992; 22: Yu J, Astrinidis A, Howard S, Henske EP: Estradiol and tamoxifen stimulate lymphangiomyomatosis-associated angiomyolipoma cell growth and activate both genomic and non-genomic signaling pathways. Am J Physiol Lung Cell Mol Physiol Kwiatkowski DJ, Zhang H, Bandura JL et al: A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70s6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: Kwiatkowski DJ: Tuberous sclerosis: from tubers to mtor. Ann Hum Genet 2003; 67: Yeung RS: Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer 2003; 38: Maheshwar MM, Cheadle JP, Jones AC et al: The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum Mol Genet 1997; 6: Roberts PS, Dabora S, Thiele EA, Franz DN, Jozwiak S, Kwiatkowski DJ: Somatic mosaicism is rare in unaffected parents of patients with sporadic tuberous sclerosis. J Med Genet 2004; 41: e69.

Diagnosing TSC by Making Clinical Connections

Diagnosing TSC by Making Clinical Connections Diagnosing TSC by Making Clinical Connections TSC = tuberous sclerosis complex. Diagnosing tuberous sclerosis complex: MORE CLUES Definite Diagnosis of Tuberous Sclerosis Complex (TSC) Possible Diagnosis

More information

Differential localisation of hamartin and tuberin and increased S6 phosphorylation in a tuber

Differential localisation of hamartin and tuberin and increased S6 phosphorylation in a tuber Differential localisation of hamartin and tuberin in a tuber 10 Differential localisation of hamartin and tuberin and increased S6 phosphorylation in a tuber Floor Jansen*, Robbert Notenboom*, Mark Nellist*,

More information

PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)

PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above) Stage I: Rule-Out Dashboard GENE/GENE PANEL: TSC1, TSC2 DISORDER: Tuberous Sclerosis Complex (TSC) HGNC ID: 12362, 12363 OMIM ID: 191100, 613254 ACTIONABILITY 1. Is there a qualifying resource, such as

More information

Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis

Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis Clin Genet 2012: 82: 552 557 Printed in Singapore. All rights reserved Short Report 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd CLINICAL GENETICS doi: 10.1111/j.1399-0004.2012.01845.x

More information

Teleconference on Tuberous Sclerosis Complex (TSC) Research October 28 th, 2008 and November 11 th, 2008

Teleconference on Tuberous Sclerosis Complex (TSC) Research October 28 th, 2008 and November 11 th, 2008 Wong 1 Teleconference on Tuberous Sclerosis Complex (TSC) Research October 28 th, 2008 and November 11 th, 2008 Sponsored by the Tuberous Sclerosis Alliance Faculty Participants: Elizabeth Henske, MD,

More information

Tuberous Sclerosis Complex

Tuberous Sclerosis Complex Tuberous Sclerosis Complex A successful transition from the bench to the bedside Mary Kay Koenig, MD The University of Texas Medical School at Houston Children s Memorial Hermann Hospital University of

More information

Molecular-genetic diagnostics of Tuberous sclerosis complex (TSC) in Bulgaria: six novel. mutations in the TSC1 and TSC2 genes

Molecular-genetic diagnostics of Tuberous sclerosis complex (TSC) in Bulgaria: six novel. mutations in the TSC1 and TSC2 genes RESEARCH ARTICLE Molecular-genetic diagnostics of Tuberous sclerosis complex (TSC) in Bulgaria: six novel mutations in the TSC1 and TSC2 genes Running title: Six novel TSC mutations in Bulgaria Glushkova

More information

MRC-Holland MLPA. Description version 29; 31 July 2015

MRC-Holland MLPA. Description version 29; 31 July 2015 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082

More information

Approach to the Genetic Diagnosis of Neurological Disorders

Approach to the Genetic Diagnosis of Neurological Disorders Approach to the Genetic Diagnosis of Neurological Disorders Dr Wendy Jones MBBS MRCP Great Ormond Street Hospital for Children National Hospital for Neurology and Neurosurgery What is a genetic diagnosis?

More information

Letters to the Editor

Letters to the Editor Letters to the Editor Am. J. Hum. Genet. 65:1790, 1999 Complete Inactivation of the TSC2 Gene Leads to Formation of Hamartomas To the Editor: Tuberous sclerosis complex (TSC [MIM 191092]), a dominantly

More information

Imaging of tuberous sclerosis complex

Imaging of tuberous sclerosis complex Imaging of tuberous sclerosis complex Poster No.: C-0388 Congress: ECR 2015 Type: Educational Exhibit Authors: M. V. Vu#kovi#, N. Menkovic, A. Petkovic, S. Ognjanovic, 1 2 1 1 1 1 1 1 J. Markov, M. Ilic,

More information

MRC-Holland MLPA. Description version 08; 30 March 2015

MRC-Holland MLPA. Description version 08; 30 March 2015 SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.

More information

MRC-Holland MLPA. Description version 30; 06 June 2017

MRC-Holland MLPA. Description version 30; 06 June 2017 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are

More information

Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors

Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors http://www.kidney-international.org & 2006 International Society of Nephrology original article Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors SK Rakowski

More information

Herczegfalvi Ágnes. Tuberous sclerosis. Case history. SE. II. sz. Gyermekklinika. Budapest, Febr

Herczegfalvi Ágnes. Tuberous sclerosis. Case history. SE. II. sz. Gyermekklinika. Budapest, Febr Herczegfalvi Ágnes Tuberous sclerosis Case history SE. II. sz. Gyermekklinika Budapest, Febr. 2016. Case history 1. GD. DOB: 05-03-1989 Pre and perinatal history: normal His development was normal till

More information

New Hope for Management of Tuberous Sclerosis. Anil Kapoor, MD, FRCSC Professor of Surgery (Urology), McMaster University Hamilton, Ontario

New Hope for Management of Tuberous Sclerosis. Anil Kapoor, MD, FRCSC Professor of Surgery (Urology), McMaster University Hamilton, Ontario New Hope for Management of Tuberous Sclerosis Anil Kapoor, MD, FRCSC Professor of Surgery (Urology), McMaster University Hamilton, Ontario Tuberous Sclerosis Complex (TSC) Incidence 1:6000 Genetic disorder

More information

CASE REPORT. FAMILIAL TUBEROUS SCLEROSIS: A CASE REPORT M. Manjukeshwari 1, S. Chidambaranathan 2

CASE REPORT. FAMILIAL TUBEROUS SCLEROSIS: A CASE REPORT M. Manjukeshwari 1, S. Chidambaranathan 2 FAMILIAL TUBEROUS SCLEROSIS: A M. Manjukeshwari 1, S. Chidambaranathan 2 HOW TO CITE THIS ARTICLE: M. Manjukeshwari, S. Chidambaranathan. Familial Tuberous Sclerosis: A Case Report. Journal of Evolution

More information

MRC-Holland MLPA. Description version 19;

MRC-Holland MLPA. Description version 19; SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL

More information

SALSA MLPA KIT P060-B2 SMA

SALSA MLPA KIT P060-B2 SMA SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the

More information

Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations

Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations Nellist et al. BMC Medical Genetics (2015) 16:10 DOI 10.1186/s12881-015-0155-4 RESEARCH ARTICLE Open Access Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations Mark

More information

Survey of Somatic Mutations in Tuberous Sclerosis Complex (TSC) Hamartomas Suggests Different Genetic Mechanisms for Pathogenesis of TSC Lesions

Survey of Somatic Mutations in Tuberous Sclerosis Complex (TSC) Hamartomas Suggests Different Genetic Mechanisms for Pathogenesis of TSC Lesions Am. J. Hum. Genet. 69:493 503, 2001 Survey of Somatic Mutations in Tuberous Sclerosis Complex (TSC) Hamartomas Suggests Different Genetic Mechanisms for Pathogenesis of TSC Lesions Yo Niida, 1,4 Anat O.

More information

Clinical History. 29 yo woman with polyhydramnios Cardiac mass at fetal ultrasound At 35 weeks, newborn died 30 minutes after delivery

Clinical History. 29 yo woman with polyhydramnios Cardiac mass at fetal ultrasound At 35 weeks, newborn died 30 minutes after delivery CASE 1 a Clinical History 29 yo woman with polyhydramnios Cardiac mass at fetal ultrasound At 35 weeks, newborn died 30 minutes after delivery Interface between tumor and normal myocardium Smaller well-demarcated

More information

CLINICAL AND PRE CLINICAL STUDIES OF RENAL DISEASE IN TUBEROUS SCLEROSIS. Anna Hellmann Thamann

CLINICAL AND PRE CLINICAL STUDIES OF RENAL DISEASE IN TUBEROUS SCLEROSIS. Anna Hellmann Thamann CLINICAL AND PRE CLINICAL STUDIES OF RENAL DISEASE IN TUBEROUS SCLEROSIS By Anna Hellmann Thamann A thesis submitted in candidature for the degree of Master of Philosophy 2014 Department of Medical Genetics

More information

MRC-Holland MLPA. Description version 08; 18 November 2016

MRC-Holland MLPA. Description version 08; 18 November 2016 SALSA MLPA probemix P122-D1 NF1 AREA Lot D1-1016. As compared to lot C2-0312, four probes in the NF1 area and one reference probe have been removed, four reference probes have been replaced and several

More information

MRC-Holland MLPA. Description version 29;

MRC-Holland MLPA. Description version 29; SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,

More information

SALSA MLPA KIT P050-B2 CAH

SALSA MLPA KIT P050-B2 CAH SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to

More information

Tuberous Sclerosis Complex: Clinical overview

Tuberous Sclerosis Complex: Clinical overview Tuberous Sclerosis Complex: Clinical overview Elizabeth A. Thiele, MD, PhD Director, Carol and James Herscot Center for Tuberous Sclerosis Complex Director, MGH Pediatric Epilepsy Program Professor of

More information

Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series)

Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series) Original Articles 17 Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series) J. Breza jr. (Jan Breza jr.) 1, B. Novotna (Barbora Novotna) 2 Original Article 1 Department of

More information

The natural history of epilepsy in tuberous sclerosis complex

The natural history of epilepsy in tuberous sclerosis complex The natural history of epilepsy in tuberous sclerosis complex The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published

More information

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)

More information

european journal of paediatric neurology 20 (2016) 296e308 Official Journal of the European Paediatric Neurology Society

european journal of paediatric neurology 20 (2016) 296e308 Official Journal of the European Paediatric Neurology Society european journal of paediatric neurology 20 (2016) 296e308 Official Journal of the European Paediatric Neurology Society Original article The clinical profile of tuberous sclerosis complex (TSC) in the

More information

Neurocutaneous Syndromes. Phakomatoses

Neurocutaneous Syndromes. Phakomatoses Neurocutaneous Syndromes Phakomatoses Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Neurocutaneous Syndomes Definition Entities Diagnosis/ Presentation

More information

Tuberous Sclerosis: New Treatment Strategies for an Old Disease

Tuberous Sclerosis: New Treatment Strategies for an Old Disease Tuberous Sclerosis: New Treatment Strategies for an ld Disease bjectives History and Diagnostic Criteria for Tuberous Sclerosis Darcy A. Krueger, M.D., Ph.D. Tuberous Sclerosis Clinic and Research Center

More information

MRC-Holland MLPA. Description version 14; 28 September 2016

MRC-Holland MLPA. Description version 14; 28 September 2016 SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium

More information

Award Number: W81XWH TITLE: Biochemical characterisation of TSC1 and TSC2 variants identified in patients with tuberous sclerosis complex

Award Number: W81XWH TITLE: Biochemical characterisation of TSC1 and TSC2 variants identified in patients with tuberous sclerosis complex Award Number: W81XWH-07-1-0523 TITLE: Biochemical characterisation of TSC1 and TSC2 variants identified in patients with tuberous sclerosis complex PRINCIPAL INVESTIGATOR:Mark Nellist CONTRACTING ORGANIZATION:Erasmus

More information

Neurocutaneous Disorders NEUROFIBROMATOSIS 11/1/2012 NEUROFIBROMATOSIS TYPE1 GENETICS. NEUOFIBROMATOSIS type 1 Cutaneous Manifestations

Neurocutaneous Disorders NEUROFIBROMATOSIS 11/1/2012 NEUROFIBROMATOSIS TYPE1 GENETICS. NEUOFIBROMATOSIS type 1 Cutaneous Manifestations Neurocutaneous Disorders M Ammar Katerji, MD NEUROFIBROMATOSIS STURGE WEBER SYNDROME INCONTINENTIA PIGMENTI INCONTINENTIA PIGMENTI ACHROMIANS LINEAR SEBACEOUS NEVUS NEVUS UNIS LATERIS KLIPPEL-TRENAUNAY-WEBER

More information

SWISS SOCIETY OF NEONATOLOGY. A rare cause of neonatal seizures

SWISS SOCIETY OF NEONATOLOGY. A rare cause of neonatal seizures SWISS SOCIETY OF NEONATOLOGY A rare cause of neonatal seizures October 2006 2 Hagmann C, Robertson NJ, Centre for Perinatal Brain Research, Institute for Women s Health, University College London, London

More information

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment). SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:

More information

TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review

TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review Genetics and Molecular Biology Online Ahead of Print Copyright 2017, Sociedade Brasileira de Genética. Printed in Brazil DOI: http://dx.doi.org/10.1590/1678-4685-gmb-2015-0321 TSC1 and TSC2 gene mutations

More information

Tuberous Sclerosis A Radiological Perspective

Tuberous Sclerosis A Radiological Perspective November 2001 Tuberous Sclerosis A Radiological Perspective Heather Brandling-Bennett, Harvard Medical School, Year III Tuberous Sclerosis Also referred to as Bourneville s disease or tuberous sclerosis

More information

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology JULY 21, 2018 Genetics 101: SCN1A Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology Disclosures: I have no financial interests or relationships to disclose. Objectives 1. Review genetic

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes

More information

Causes of mortality in individuals with tuberous sclerosis complex

Causes of mortality in individuals with tuberous sclerosis complex DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY ORIGINAL ARTICLE Causes of mortality in individuals with tuberous sclerosis complex SAM AMIN 1 ANDREW LUX 1 NUALA CALDER 2 MATTHEW LAUGHARNE 3 JOHN OSBORNE 2 FINBAR

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Loeys-Dietz Syndrome OMIM number for disease 609192; 608967; 610380; 610168 Disease

More information

Identification of epileptogenic tubers in patients with tuberous sclerosis complex

Identification of epileptogenic tubers in patients with tuberous sclerosis complex Identification of epileptogenic tubers in patients with tuberous sclerosis complex Floortje Elisabeth Jansen ISBN: 12978-90-39344620 Cover design: Geertjan Huiskamp, Roy Sanders Lay out: Roy Sanders Printed

More information

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix. SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:

More information

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted. mix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four s have been adjusted. The sex-determining region on chromosome Y (SRY) is the most important

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0716, D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent

More information

Coexistence of Lymphangioleiomyomatosis and Angiomyolipomas in a Patient of Tuberous Sclerosis Complex: a case report

Coexistence of Lymphangioleiomyomatosis and Angiomyolipomas in a Patient of Tuberous Sclerosis Complex: a case report Chin J Radiol 2003; 28: 329-333 329 Coexistence of Lymphangioleiomyomatosis and Angiomyolipomas in a Patient of Tuberous Sclerosis Complex: a case report FENG-CHI HSIEH 1 KAO-LANG LIU 1 YIH-LEONG CHANG

More information

Everolimus in the treatment of giant renal angiomyolipoma associated with tuberous sclerosis

Everolimus in the treatment of giant renal angiomyolipoma associated with tuberous sclerosis CASE REPORT Advance Access publication 11 February 2016 Everolimus in the treatment of giant renal angiomyolipoma associated with tuberous sclerosis Miguel Oliveira 1, Marta Sofia Costa 1, Tiago Barra

More information

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted. mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised

More information

SALSA MLPA probemix P315-B1 EGFR

SALSA MLPA probemix P315-B1 EGFR SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional

More information

Computational Systems Biology: Biology X

Computational Systems Biology: Biology X Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH

More information

A Case Report on the Effect of Everolimus in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

A Case Report on the Effect of Everolimus in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex Elmer Press Case Report A Case Report on the Effect of Everolimus in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex Huma M Paika a, d, Yull E. Arriaga b, Anthony Setiawan c Abstract Tuberous

More information

Tuberous sclerosis complex (TSC) is an autosomal dominant

Tuberous sclerosis complex (TSC) is an autosomal dominant Winter/Spring 2018 A Look at the Genetics of TSC: How Important Is Genetic Testing to Patients and Their Physicians? About TSC Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder

More information

What I know best: Tuberous Sclerosis Complex

What I know best: Tuberous Sclerosis Complex What I know best: Tuberous Sclerosis Complex Prof Petrus de Vries Sue Struengmann Professor of Child & Adolescent Psychiatry University of Cape Town South Africa Red Cross War Memorial Children s Hospital,

More information

UNLOCKING A CURE FOR TUBEROUS SCLEROSIS COMPLEX. An Assessment of Scientific Progress and Research Needs

UNLOCKING A CURE FOR TUBEROUS SCLEROSIS COMPLEX. An Assessment of Scientific Progress and Research Needs UNLOCKING A CURE FOR TUBEROUS SCLEROSIS COMPLEX An Assessment of Scientific Progress and Research Needs A White Paper by: Vicky Holets Whittemore, PhD 801 Roeder Road, Suite 750 Silver Spring, MD 20910

More information

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53. SALSA MLPA probemix P056-C1 TP53 Lot C1-0215 & lot C1-0214. As compared to version B1 (lot B1-1011) most of the reference and flanking probes have been replaced and several have been added. Furthermore,

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Polycystic Kidney Disease, Autosomal Dominant OMIM number for disease 173900 Disease

More information

Clinical characteristics of tuberous sclerosis complex in patients with no TSC1 or TSC2 mutations identified

Clinical characteristics of tuberous sclerosis complex in patients with no TSC1 or TSC2 mutations identified CHILD NEUROLOGY NEUROLOGIA DZIECIĘCA Vol. 15/2006 Nr 30 PRACA ORYGINALNA/ORIGINAL ARTICLE Clinical characteristics of tuberous sclerosis complex in patients with no TSC1 or TSC2 mutations identified Charakterystyka

More information

Tuberous sclerosis with giant renal angiomyolipoma and sclerotic skeletal lesions in a geriatric patient: role of imaging

Tuberous sclerosis with giant renal angiomyolipoma and sclerotic skeletal lesions in a geriatric patient: role of imaging International Journal of Research in Medical Sciences Nagaraju RM et al. Int J Res Med Sci. 2015 Aug;3(8):2145-2149 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Case Report DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150346

More information

MRC-Holland MLPA. Description version 18; 09 September 2015

MRC-Holland MLPA. Description version 18; 09 September 2015 SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Case Report Everolimus: Paradigm Shift in the Management of Tuberous Sclerosis Dr Sabarish Mahalingam 1, Dr P. Z. Wadia

More information

Regulation of tuberous sclerosis complex (TSC) function by proteins

Regulation of tuberous sclerosis complex (TSC) function by proteins TSC Genes Novel Players in the Growth Regulation Network 587 Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins M. Nellist 1,M.A. Goedbloed and D.J.J. Halley Department of Clinical

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Słowińska et al. Orphanet Journal of Rare Diseases (2018) 13:25 DOI 10.1186/s13023-018-0764-z RESEARCH Open Access Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis

More information

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 mix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 The purpose of the P371 mix is to further investigate results found with the P245 Microdeletion mix. The P245 mix provides a possibility to screen samples

More information

MRC-Holland MLPA. Description version 12; 13 January 2017

MRC-Holland MLPA. Description version 12; 13 January 2017 SALSA MLPA probemix P219-B3 PAX6 Lot B3-0915: Compared to version B2 (lot B2-1111) two reference probes have been replaced and one additional reference probe has been added. In addition, one flanking probe

More information

Tuberous sclerosis complex is a genetic

Tuberous sclerosis complex is a genetic 60 Journal of the association of physicians of india vol 62 december, 2014 Case Reports A Case Report of Tuberous Sclerosis in Two Generations Chandrakala *, Sharanagouda Patil **, KY Guruprasad *** Abstract

More information

Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations

Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations Korean J Lab Med 2010;30:190-4 DOI 10.3343/kjlm.2010.30.2.190 Original Article Diagnostic Genetics Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report

More information

MRC-Holland MLPA. Description version 07; 26 November 2015

MRC-Holland MLPA. Description version 07; 26 November 2015 SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced

More information

Best Practice Guidelines for Molecular Analysis of Retinoblastoma

Best Practice Guidelines for Molecular Analysis of Retinoblastoma Best Practice Guidelines for Molecular Analysis of Retinoblastoma Lohmann D 1, Scheffer H 2, Gaille B 3 1 Institut für Humangenetik, Universitätsklinikum Essen, Germany. 2 Dept. Human Genetics, University

More information

Pediatric Neurology 49 (2013) 255e265. Contents lists available at ScienceDirect. Pediatric Neurology

Pediatric Neurology 49 (2013) 255e265. Contents lists available at ScienceDirect. Pediatric Neurology Pediatric Neurology 49 (2013) 255e265 Contents lists available at ScienceDirect Pediatric Neurology journal homepage: www. elsevier. com/ locate/ pnu Original Article Tuberous Sclerosis Complex Surveillance

More information

Non-Mendelian inheritance

Non-Mendelian inheritance Non-Mendelian inheritance Focus on Human Disorders Peter K. Rogan, Ph.D. Laboratory of Human Molecular Genetics Children s Mercy Hospital Schools of Medicine & Computer Science and Engineering University

More information

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B1-0613. The purpose of the P372 probemix is to further investigate results found with the P245 Microdeletion Syndromes-1A probemix. The

More information

Tuberous Sclerosis Complex

Tuberous Sclerosis Complex Edited by David J. Kwiatkowski, Vicky Holets Whittemore, and Elizabeth A. Thiele Tuberous Sclerosis Complex Genes, Clinical Features, and Therapeutics Edited by David J. Kwiatkowski, Vicky Holets Whittemore,

More information

1 The History of Tuberous Sclerosis Complex

1 The History of Tuberous Sclerosis Complex j1 Part I Basics Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics Edited by David J. Kwiatkowski, Vicky Holets Whittemore, and Elizabeth A. Thiele Copyright Ó 2010 WILEY-VCH Verlag

More information

MRC-Holland MLPA. Description version 06; 23 December 2016

MRC-Holland MLPA. Description version 06; 23 December 2016 SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated

More information

Carl Ludwig Behnes 1*, Gunther Schütze 2, Christoph Engelke 3, Felix Bremmer 1, Bastian Gunawan 1, Heinz-Joachim Radzun 1 and Stefan Schweyer 1

Carl Ludwig Behnes 1*, Gunther Schütze 2, Christoph Engelke 3, Felix Bremmer 1, Bastian Gunawan 1, Heinz-Joachim Radzun 1 and Stefan Schweyer 1 Behnes et al. BMC Clinical Pathology 2013, 13:4 CASE REPORT Open Access 13-year-old tuberous sclerosis patient with renal cell carcinoma associated with multiple renal angiomyolipomas developing multifocal

More information

Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome

Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome L.H. Cao 1, B.H. Kuang 2, C. Chen 1, C. Hu 2, Z. Sun 1, H. Chen 2, S.S. Wang

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)

More information

Introduction. Seyyed Hassan Tonekaboni MD 1, Parviz Tousi MD 2,

Introduction. Seyyed Hassan Tonekaboni MD 1, Parviz Tousi MD 2, original ARTICLE Clinical and Para clinical Manifestations of Tuberous Sclerosis: A Cross Sectional Study on 81 Pediatric Patients How to Cite this Article: Tonekaboni SH, Tousi P, Ebrahimi A, Ahmadabadi

More information

Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex

Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex Human Molecular Genetics, 2014, Vol. 23, No. 8 2023 2029 doi:10.1093/hmg/ddt597 Advance Access published on November 23, 2013 Sun exposure causes somatic second-hit mutations and angiofibroma development

More information

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our 1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented

More information

Germ-Line Mutational Analysis of the TSC2 Gene in 90 Tuberous-Sclerosis Patients

Germ-Line Mutational Analysis of the TSC2 Gene in 90 Tuberous-Sclerosis Patients Am. J. Hum. Genet. 62:286 294, 1998 Germ-Line Mutational Analysis of the TSC2 Gene in 90 Tuberous-Sclerosis Patients Kit-Sing Au, 1, Joseph A. Rodriguez, 1, Jennifer L. Finch, 1 Kelly A. Volcik, 1 E. Steve

More information

Tuberous Sclerosis Complex A Review for Health Care Professionals

Tuberous Sclerosis Complex A Review for Health Care Professionals Renal Lesions in Patients With Tuberous Sclerosis Complex A Review for Health Care Professionals ONGOING SURVEILLANCE IS CRITICAL TO MONITOR THE PROGRESSION OFIntroduction KNOWN SYMPTOMS AND THE EMERGENCE

More information

Tuberous Sclerosis Alliance and Tuberous Sclerosis Complex Clinics Scope of Relationship Policy

Tuberous Sclerosis Alliance and Tuberous Sclerosis Complex Clinics Scope of Relationship Policy Tuberous Sclerosis Alliance and Tuberous Sclerosis Complex Clinics Scope of Relationship Policy ROLE OF THE TSC CLINIC A Tuberous Sclerosis Complex (TSC) Clinic is defined as a group of board-certified

More information

MRC-Holland MLPA. Description version 08; 07 May 2015

MRC-Holland MLPA. Description version 08; 07 May 2015 mix P185-C1 Intersex Lot C1-0611: As compared to the previous version B2 (lot B2-0311), s for CYP21A2 have been removed and s for the CXorf21 gene as well as additional s for NR0B1, NR5A1 and the Y chromosome

More information

Introduction to genetic variation. He Zhang Bioinformatics Core Facility 6/22/2016

Introduction to genetic variation. He Zhang Bioinformatics Core Facility 6/22/2016 Introduction to genetic variation He Zhang Bioinformatics Core Facility 6/22/2016 Outline Basic concepts of genetic variation Genetic variation in human populations Variation and genetic disorders Databases

More information

Advances in genetic diagnosis of neurological disorders

Advances in genetic diagnosis of neurological disorders Acta Neurol Scand 2014: 129 (Suppl. 198): 20 25 DOI: 10.1111/ane.12232 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Review Article Advances in genetic diagnosis

More information

Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016

Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Marwan Tayeh, PhD, FACMG Director, MMGL Molecular Genetics Assistant Professor of Pediatrics Department of Pediatrics

More information

Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns

Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns جواد کریمزاد حق PhD of Medical Genetics آزمايشگاه پاتوبيولوژي و ژنتيك پارسه

More information

Lymphangioleiomyomatosis (LAM) is a devastating interstitial

Lymphangioleiomyomatosis (LAM) is a devastating interstitial Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis Thomas Carsillo, Aristotelis Astrinidis, and Elizabeth Petri Henske* Department of Medical

More information

ASSOCIATION LUPUS AND TUBEROUS SCLEROSIS: IS IT POSSIBLE? THE INVOLVEMENT OF MTOR PATHEWAY

ASSOCIATION LUPUS AND TUBEROUS SCLEROSIS: IS IT POSSIBLE? THE INVOLVEMENT OF MTOR PATHEWAY wjpmr, 2017,3(6), 76-80 SJIF Impact Factor: 4.103 Rahima et al. Research Article WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH ISSN 2455-3301 www.wjpmr.com WJPMR ASSOCIATION LUPUS AND TUBEROUS SCLEROSIS:

More information

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi 2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000

More information

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why

More information

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A1-1011. This SALSA MLPA probemix is for basic research and intended for experienced MLPA users only! This probemix enables you to quantify genes

More information

Problem Set 5 KEY

Problem Set 5 KEY 2006 7.012 Problem Set 5 KEY ** Due before 5 PM on THURSDAY, November 9, 2006. ** Turn answers in to the box outside of 68-120. PLEASE WRITE YOUR ANSWERS ON THIS PRINTOUT. 1. You are studying the development

More information

Endocrine Surgery. Characteristics of the Germline MEN1 Mutations in Korea: A Literature Review ORIGINAL ARTICLE. The Korean Journal of INTRODUCTION

Endocrine Surgery. Characteristics of the Germline MEN1 Mutations in Korea: A Literature Review ORIGINAL ARTICLE. The Korean Journal of INTRODUCTION ORIGINAL ARTICLE ISSN 1598-1703 (Print) ISSN 2287-6782 (Online) Korean J Endocrine Surg 2014;14:7-11 The Korean Journal of Endocrine Surgery Characteristics of the Germline MEN1 Mutations in Korea: A Literature

More information